JP2019506397A - モートン神経腫疼痛の治療のためのカプサイシン連続投薬方法 - Google Patents

モートン神経腫疼痛の治療のためのカプサイシン連続投薬方法 Download PDF

Info

Publication number
JP2019506397A
JP2019506397A JP2018538168A JP2018538168A JP2019506397A JP 2019506397 A JP2019506397 A JP 2019506397A JP 2018538168 A JP2018538168 A JP 2018538168A JP 2018538168 A JP2018538168 A JP 2018538168A JP 2019506397 A JP2019506397 A JP 2019506397A
Authority
JP
Japan
Prior art keywords
capsaicin
dose
pain
metatarsal
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018538168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506397A5 (enExample
Inventor
ジェイムズ・エヌ・キャンベル
ピーター・ディ・ハンソン
ランドール・スティーブンズ
Original Assignee
セントレクシオン セラピューティクス コーポレイション
セントレクシオン セラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントレクシオン セラピューティクス コーポレイション, セントレクシオン セラピューティクス コーポレイション filed Critical セントレクシオン セラピューティクス コーポレイション
Publication of JP2019506397A publication Critical patent/JP2019506397A/ja
Publication of JP2019506397A5 publication Critical patent/JP2019506397A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2018538168A 2016-01-22 2017-01-20 モートン神経腫疼痛の治療のためのカプサイシン連続投薬方法 Pending JP2019506397A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281877P 2016-01-22 2016-01-22
US62/281,877 2016-01-22
PCT/US2017/014257 WO2017127628A1 (en) 2016-01-22 2017-01-20 Capsaicn sequential dosing method for treatment of morton's neuroma pain

Publications (2)

Publication Number Publication Date
JP2019506397A true JP2019506397A (ja) 2019-03-07
JP2019506397A5 JP2019506397A5 (enExample) 2020-02-27

Family

ID=59362242

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018538168A Pending JP2019506397A (ja) 2016-01-22 2017-01-20 モートン神経腫疼痛の治療のためのカプサイシン連続投薬方法

Country Status (7)

Country Link
US (2) US20190022036A1 (enExample)
EP (1) EP3405187A4 (enExample)
JP (1) JP2019506397A (enExample)
CN (1) CN108697673A (enExample)
AU (1) AU2017210315A1 (enExample)
CA (1) CA3011647A1 (enExample)
WO (1) WO2017127628A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7100635B2 (ja) 2016-11-02 2022-07-13 セントレクシオン セラピューティクス コーポレイション 安定な水性カプサイシン注射製剤およびその医学的使用
IL272036B2 (en) 2017-07-20 2025-01-01 Centrexion Therapeutics Corp Methods and compositions for treating pain using capsaicin
JP2021534207A (ja) * 2018-08-24 2021-12-09 セントレクシオン セラピューティクス コーポレイション 膝関節痛の治療のためのカプサイシン連続投薬方法
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019436A1 (en) * 2002-12-18 2005-01-27 Algorx Injectable capsaicin
JP2014527964A (ja) * 2011-09-09 2014-10-23 エイピーアイ・ジェネシス，エルエルシー Ｔｒｐｖ１選択的アゴニストを含む疼痛軽減組成物、ならびにその製造および使用
JP2015536998A (ja) * 2012-11-12 2015-12-24 エイピーアイ・ジェネシス，エルエルシー 水性カプサイシノイド配合物ならびにその製造法および使用法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161481A1 (en) * 2002-12-18 2004-08-19 Algorx Administration of capsaicinoids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019436A1 (en) * 2002-12-18 2005-01-27 Algorx Injectable capsaicin
JP2006513267A (ja) * 2002-12-18 2006-04-20 アルゴルクス ファーマスーティカルズ，インク カプサイシノイドの投与
JP2014527964A (ja) * 2011-09-09 2014-10-23 エイピーアイ・ジェネシス，エルエルシー Ｔｒｐｖ１選択的アゴニストを含む疼痛軽減組成物、ならびにその製造および使用
JP2015536998A (ja) * 2012-11-12 2015-12-24 エイピーアイ・ジェネシス，エルエルシー 水性カプサイシノイド配合物ならびにその製造法および使用法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANESTH ANALG, vol. 86, JPN6022021481, 1998, pages 579 - 583, ISSN: 0004781856 *
LIFE SCIENCES, vol. 51, no. 23, JPN6022021480, 1992, pages 1767 - 1775, ISSN: 0004781857 *

Also Published As

Publication number Publication date
US20200297670A1 (en) 2020-09-24
EP3405187A4 (en) 2019-07-31
CA3011647A1 (en) 2017-07-27
CN108697673A (zh) 2018-10-23
US20190022036A1 (en) 2019-01-24
AU2017210315A1 (en) 2018-08-16
WO2017127628A1 (en) 2017-07-27
EP3405187A1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
US20200297670A1 (en) Capsaicin Sequential Dosing Method for Treatment of Morton's Neuroma Pain
US20250312298A1 (en) Methods and compositions for treatment of pain using capsaicin
EA004101B1 (ru) Применение селективных ингибиторов обратного захвата серотонина быстрого запуска для лечения половой дисфункции
JPH0780761B2 (ja) 痛みのある疾患又はアレルギー性疾患の治療用組成物及び治療法
US20210145772A1 (en) Capsaicinoids for use in treating acral lick granuloma
CN105209044B (zh) 用于疼痛病症的治疗性米氮平组合物
RU2633637C2 (ru) Паралитический яд моллюсков
WO2014190063A1 (en) Methods for the treatment of premature ejaculation
US6620423B2 (en) Use for pain management
US20220395472A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
EP3840739B1 (en) Capsaicin sequential dosing method for treatment of knee joint pain
US20220265572A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
JP4253371B2 (ja) 筋クランプ治療剤
WO2024226995A1 (en) Compositions and methods for treating post-traumatic stress disorder
US20030162769A1 (en) Composition and method for treating vulvodynia
HK40031064B (en) Compositions and their use for treatment of pain using capsaicin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220301

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220301

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220329

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220502

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220510

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220527

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220531